Skip to main content
. 2024 Feb 15;31(2):1047–1062. doi: 10.3390/curroncol31020078

Figure 1.

Figure 1

Proposed overview for the management of low-volume or -risk metastatic castration-sensitive prostate cancer (CSPC). High risk definition (from LATITUDE) [7]: at least 2 of the following: ≥3 bone metastases, visceral metastases, Gleason score ≥8. High volume definition (from CHAARTED) [13]: at least 1 of the following: ≥4 bone lesions with ≥1 beyond the vertebral bodies and pelvis or visceral metastases. * = Data for the use of docetaxel in low-volume disease is limited, see text for further discussion.